Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Magdalena Żurawek x
Clear All Modify Search
Marta Fichna Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

Search for other papers by Marta Fichna in
Google Scholar
PubMed
Close
,
Piotr P Małecki Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

Search for other papers by Piotr P Małecki in
Google Scholar
PubMed
Close
,
Magdalena Żurawek Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland

Search for other papers by Magdalena Żurawek in
Google Scholar
PubMed
Close
,
Katarzyna Furman Ludwik Perzyna Regional Hospital, Kalisz, Poland

Search for other papers by Katarzyna Furman in
Google Scholar
PubMed
Close
,
Bolesław Gębarski Regional Outpatient Medical Centre, Katowice, Poland

Search for other papers by Bolesław Gębarski in
Google Scholar
PubMed
Close
,
Piotr Fichna Department of Paediatric Diabetes and Obesity, Poznan University of Medical Sciences, Poznan, Poland

Search for other papers by Piotr Fichna in
Google Scholar
PubMed
Close
, and
Marek Ruchała Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland

Search for other papers by Marek Ruchała in
Google Scholar
PubMed
Close

Since individuals with Addison’s disease (AD) present considerable co-occurrence of additional autoimmune conditions, clustering of autoimmunity was also predicted among their relatives. The study was aimed to assess circulating autoantibodies in first-degree relatives of patients with AD and to correlate them with the established genetic risk factors (PTPN22 rs2476601, CTLA4 rs231775, and BACH2 rs3757247). Antibodies were evaluated using validated commercial assays, and genotyping was performed using TaqMan chemistry. The studied cohort comprised 112 female and 75 male relatives. Circulating autoantibodies were found in 69 relatives (36.9%). Thyroid autoantibodies, that is antibodies to thyroid peroxidase (aTPO) and thyroglobulin (aTg), were detectable in 25.1 and 17.1% relatives, respectively. Antibodies to 21-hydroxylase (a21OH) were found in 5.8% individuals, and beta cell-specific antibodies to ZnT8, GAD, and IA2 were found in 7.5, 8.0, and 2.7%, respectively. The prevalence of a21OH (P = 0.0075; odds ratio (OR) 7.68; 95% CI 1.903–36.0), aTPO (P < 0.0001; OR 3.85; 95% CI 1.873–7.495), and aTg (P < 0.0001; OR 7.73; 95% CI 3.112–19.65), as well as aGAD (P = 0.0303; OR 3.38; 95% CI 1.180–9.123) and aZnT8 (P = 0.032; OR 6.40; 95% CI 1.846–21.91), was significantly increased in carriers of rs2476601 T allele. Moreover, T allele appeared to be a risk factor for multiple circulating autoantibody specificities (P = 0.0009; OR 5.79; 95% CI 1.962–15.81). None of the studied autoantibodies demonstrated significant association with rs231775 in CTLA4 (P > 0.05), and only weak association was detected between BACH2 rs3757247 and circulating aTPO (P = 0.0336; OR 2.12; 95%CI 1.019–4.228). In conclusion, first-degree relatives of patients with AD, carriers of the PTPN22 rs2476601 T allele, are at particular risk of developing autoantibodies to endocrine antigens.

Open access